The latest price target for GeneDx Holdings (NASDAQ:WGS) was reported by Canaccord Genuity on May 5, 2026. The analyst firm set a price target for $75.00 expecting WGS to rise to within 12 months (a possible 27.10% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for GeneDx Holdings (NASDAQ:WGS) was provided by Canaccord Genuity, and GeneDx Holdings maintained their buy rating.

The last upgrade for GeneDx Holdings Corp happened on February 9, 2026 when Wells Fargo raised their price target to $155. Wells Fargo previously had an equal-weight for GeneDx Holdings Corp.

There is no last downgrade for GeneDx Holdings.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Holdings was filed on May 5, 2026 so you should expect the next rating to be made available sometime around May 5, 2027.

While ratings are subjective and will change, the latest GeneDx Holdings (WGS) rating was a maintained with a price target of $100.00 to $75.00. The current price GeneDx Holdings (WGS) is trading at is $59.01, which is out of the analyst’s predicted range.